Chapter/Section Purchase

1 Novel Oral AntiCoagulants (NOAC) Market Overview
1.1 Product Overview and Scope of Novel Oral AntiCoagulants (NOAC)
1.2 Novel Oral AntiCoagulants (NOAC) Segment by Type
1.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Direct Thrombin Inhibitors
1.2.3 Direct Factor Xa Inhibitors
1.3 Novel Oral AntiCoagulants (NOAC) Segment by Application
1.3.1 Global Novel Oral AntiCoagulants (NOAC) Sales Comparison by Application: (2022-2028)
1.3.2 Deep Vein Thrombosis (DVT)
1.3.3 Pulmonary Embolism
1.3.4 Acute Coronary Syndrome
1.3.5 Hemodialysis
1.3.6 Others
1.4 Global Novel Oral AntiCoagulants (NOAC) Market Size Estimates and Forecasts
1.4.1 Global Novel Oral AntiCoagulants (NOAC) Revenue 2017-2028
1.4.2 Global Novel Oral AntiCoagulants (NOAC) Sales 2017-2028
1.4.3 Novel Oral AntiCoagulants (NOAC) Market Size by Region: 2017 Versus 2021 Versus 2028
2 Novel Oral AntiCoagulants (NOAC) Market Competition by Manufacturers
2.1 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Manufacturers (2017-2022)
2.2 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Novel Oral AntiCoagulants (NOAC) Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Novel Oral AntiCoagulants (NOAC) Manufacturing Sites, Area Served, Product Type
2.5 Novel Oral AntiCoagulants (NOAC) Market Competitive Situation and Trends
2.5.1 Novel Oral AntiCoagulants (NOAC) Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Novel Oral AntiCoagulants (NOAC) Players Market Share by Revenue
2.5.3 Global Novel Oral AntiCoagulants (NOAC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Novel Oral AntiCoagulants (NOAC) Retrospective Market Scenario by Region
3.1 Global Novel Oral AntiCoagulants (NOAC) Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Novel Oral AntiCoagulants (NOAC) Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country
3.3.1 North America Novel Oral AntiCoagulants (NOAC) Sales by Country
3.3.2 North America Novel Oral AntiCoagulants (NOAC) Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country
3.4.1 Europe Novel Oral AntiCoagulants (NOAC) Sales by Country
3.4.2 Europe Novel Oral AntiCoagulants (NOAC) Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Region
3.5.1 Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales by Region
3.5.2 Asia Pacific Novel Oral AntiCoagulants (NOAC) Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country
3.6.1 Latin America Novel Oral AntiCoagulants (NOAC) Sales by Country
3.6.2 Latin America Novel Oral AntiCoagulants (NOAC) Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Market Facts & Figures by Country
3.7.1 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country
3.7.2 Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Novel Oral AntiCoagulants (NOAC) Historic Market Analysis by Type
4.1 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2017-2022)
4.2 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2017-2022)
4.3 Global Novel Oral AntiCoagulants (NOAC) Price by Type (2017-2022)
5 Global Novel Oral AntiCoagulants (NOAC) Historic Market Analysis by Application
5.1 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2017-2022)
5.2 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2017-2022)
5.3 Global Novel Oral AntiCoagulants (NOAC) Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Corporation Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Bristol-Myers Squibb
6.2.1 Bristol-Myers Squibb Corporation Information
6.2.2 Bristol-Myers Squibb Description and Business Overview
6.2.3 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.2.5 Bristol-Myers Squibb Recent Developments/Updates
6.3 Boehringer Ingelheim
6.3.1 Boehringer Ingelheim Corporation Information
6.3.2 Boehringer Ingelheim Description and Business Overview
6.3.3 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.3.5 Boehringer Ingelheim Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Daiichi Sankyo
6.5.1 Daiichi Sankyo Corporation Information
6.5.2 Daiichi Sankyo Description and Business Overview
6.5.3 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.5.5 Daiichi Sankyo Recent Developments/Updates
6.6 Armatheon
6.6.1 Armatheon Corporation Information
6.6.2 Armatheon Description and Business Overview
6.6.3 Armatheon Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.6.5 Armatheon Recent Developments/Updates
6.7 Aspen
6.6.1 Aspen Corporation Information
6.6.2 Aspen Description and Business Overview
6.6.3 Aspen Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.7.5 Aspen Recent Developments/Updates
6.8 AstraZeneca
6.8.1 AstraZeneca Corporation Information
6.8.2 AstraZeneca Description and Business Overview
6.8.3 AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.8.4 AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.8.5 AstraZeneca Recent Developments/Updates
6.9 Bayer
6.9.1 Bayer Corporation Information
6.9.2 Bayer Description and Business Overview
6.9.3 Bayer Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.9.5 Bayer Recent Developments/Updates
6.10 Cellceutix
6.10.1 Cellceutix Corporation Information
6.10.2 Cellceutix Description and Business Overview
6.10.3 Cellceutix Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.10.5 Cellceutix Recent Developments/Updates
6.11 Cosmo Pharmaceuticals
6.11.1 Cosmo Pharmaceuticals Corporation Information
6.11.2 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Description and Business Overview
6.11.3 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.11.5 Cosmo Pharmaceuticals Recent Developments/Updates
6.12 CSL Behring
6.12.1 CSL Behring Corporation Information
6.12.2 CSL Behring Novel Oral AntiCoagulants (NOAC) Description and Business Overview
6.12.3 CSL Behring Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.12.4 CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.12.5 CSL Behring Recent Developments/Updates
6.13 Eisai
6.13.1 Eisai Corporation Information
6.13.2 Eisai Novel Oral AntiCoagulants (NOAC) Description and Business Overview
6.13.3 Eisai Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.13.5 Eisai Recent Developments/Updates
6.14 GSK
6.14.1 GSK Corporation Information
6.14.2 GSK Novel Oral AntiCoagulants (NOAC) Description and Business Overview
6.14.3 GSK Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.14.4 GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.14.5 GSK Recent Developments/Updates
6.15 Marathon Pharmaceuticals
6.15.1 Marathon Pharmaceuticals Corporation Information
6.15.2 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Description and Business Overview
6.15.3 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.15.5 Marathon Pharmaceuticals Recent Developments/Updates
6.16 Ockham Biotech
6.16.1 Ockham Biotech Corporation Information
6.16.2 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Description and Business Overview
6.16.3 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.16.5 Ockham Biotech Recent Developments/Updates
6.17 Perosphere
6.17.1 Perosphere Corporation Information
6.17.2 Perosphere Novel Oral AntiCoagulants (NOAC) Description and Business Overview
6.17.3 Perosphere Novel Oral AntiCoagulants (NOAC) Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio
6.17.5 Perosphere Recent Developments/Updates
7 Novel Oral AntiCoagulants (NOAC) Manufacturing Cost Analysis
7.1 Novel Oral AntiCoagulants (NOAC) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Novel Oral AntiCoagulants (NOAC)
7.4 Novel Oral AntiCoagulants (NOAC) Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Novel Oral AntiCoagulants (NOAC) Distributors List
8.3 Novel Oral AntiCoagulants (NOAC) Customers
9 Novel Oral AntiCoagulants (NOAC) Market Dynamics
9.1 Novel Oral AntiCoagulants (NOAC) Industry Trends
9.2 Novel Oral AntiCoagulants (NOAC) Market Drivers
9.3 Novel Oral AntiCoagulants (NOAC) Market Challenges
9.4 Novel Oral AntiCoagulants (NOAC) Market Restraints
10 Global Market Forecast
10.1 Novel Oral AntiCoagulants (NOAC) Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Novel Oral AntiCoagulants (NOAC) by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Novel Oral AntiCoagulants (NOAC) by Type (2023-2028)
10.2 Novel Oral AntiCoagulants (NOAC) Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Novel Oral AntiCoagulants (NOAC) by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Novel Oral AntiCoagulants (NOAC) by Application (2023-2028)
10.3 Novel Oral AntiCoagulants (NOAC) Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Novel Oral AntiCoagulants (NOAC) by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Novel Oral AntiCoagulants (NOAC) by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer